NextCure Inc (NXTC) FinancialsNXTCFinancialNextCure Inc

Evaluating the bottom line, NextCure Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -195.22%, provide a clear picture of how effectively NXTC converts its operational activities into shareholder value.

In the context of the broader market, NXTC competes directly with industry leaders such as BYSI and LTRN. With a market capitalization of $37.58M, it holds a leading position in the sector. When comparing efficiency, NXTC's gross margin of N/A stands against BYSI's N/A and LTRN's N/A. Such benchmarking helps identify whether NextCure Inc is trading at a premium or discount relative to its financial performance.

NextCure has shown a volatile financial performance with a recent net income loss of $14,892,000 in Q2 2026 and a forward P/E ratio of 0, indicating no earnings expected in the near term. However, the company has a strong current ratio of 3.47, suggesting good short-term liquidity.